FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281996388> ?p ?o ?g. }

• W4281996388 endingPage "i93" @default.
• W4281996388 startingPage "i93" @default.
• W4281996388 abstract "Abstract Ulixertinib (BVD-523) is a catalytic ERK1/2 inhibitor that showed promising responses in adult patients with mitogen-activated protein kinase (MAPK)-driven solid tumors. Pediatric low-grade gliomas (pLGG) are the most common pediatric brain tumors, with the most frequent driving alterations in the MAPK pathway. The anti-tumor activity of ulixertinib in pLGG and its potential synergism in combination with MEK inhibitors, senolytics, and chemotherapy were investigated in vitro using metabolic activity, MAPK reporter assay and high-content microscopy in pLGG-derived cell lines (DKFZ-BT66 - KIAA:BRAF fusion; BT40 - BRAF V600E mutation and CDKN2A/B deletion). The most clinically relevant combinations were further validated in vivo: 1) in zebrafish embryo models (BT40 and DKFZ-BT66 yolk sac injection) and 2) in NSG mice (BT40 orthotopic PDX) including in vivo pharmacokinetic and -dynamic analyses. Ulixertinib inhibited MAPK pathway activity in all models and reduced cell viability in the BRAF V600E mutated cell line at concentrations in the nanomolar range. In vivo pharmacokinetic and -dynamic analyses showed penetrance of the drug into mouse brain tissue and on-target activity, with concentrations above the in vitro IC50 and reduction of MAPK activity. Ulixertinib treatment slowed tumor growth and significantly increased survival in NSG mice with BT40 xenografts. Ulixertinib showed indications for anti-proliferative synergy in vitro in combination with MEK inhibitors (trametinib, binimetinib) or BH3 mimetics (navitoclax, A-1331852). Combinations with chemotherapy (carboplatin, vinblastine) were at most additive. Indications for synergy with binimetinib and navitoclax were confirmed in the zebrafish embryo models. In the NSG mouse model, the combination of ulixertinib with senolytics induced effects on tumor growth and survival comparable to ulixertinib monotherapy. Ulixertinib shows promising potential as a clinically relevant therapeutic option for the treatment of pLGG to be further investigated in upcoming clinical trials. Potential synergism with MEK inhibitors and BH3 mimetics was noted and warrants further investigation." @default.
• W4281996388 created "2022-06-13" @default.
• W4281996388 creator A5000373937 @default.
• W4281996388 creator A5000865600 @default.
• W4281996388 creator A5002676459 @default.
• W4281996388 creator A5003000553 @default.
• W4281996388 creator A5004020500 @default.
• W4281996388 creator A5013368889 @default.
• W4281996388 creator A5017416578 @default.
• W4281996388 creator A5019496707 @default.
• W4281996388 creator A5019911093 @default.
• W4281996388 creator A5021921614 @default.
• W4281996388 creator A5031520036 @default.
• W4281996388 creator A5032226480 @default.
• W4281996388 creator A5037244584 @default.
• W4281996388 creator A5041096535 @default.
• W4281996388 creator A5046393641 @default.
• W4281996388 creator A5051018235 @default.
• W4281996388 creator A5054614170 @default.
• W4281996388 creator A5057303452 @default.
• W4281996388 creator A5064456190 @default.
• W4281996388 creator A5069043826 @default.
• W4281996388 creator A5076344546 @default.
• W4281996388 creator A5081253005 @default.
• W4281996388 creator A5087140172 @default.
• W4281996388 creator A5088160001 @default.
• W4281996388 creator A5090138684 @default.
• W4281996388 date "2022-06-01" @default.
• W4281996388 modified "2023-10-06" @default.
• W4281996388 title "LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics" @default.
• W4281996388 doi "https://doi.org/10.1093/neuonc/noac079.339" @default.
• W4281996388 hasPublicationYear "2022" @default.
• W4281996388 type Work @default.
• W4281996388 citedByCount "0" @default.
• W4281996388 crossrefType "journal-article" @default.
• W4281996388 hasAuthorship W4281996388A5000373937 @default.
• W4281996388 hasAuthorship W4281996388A5000865600 @default.
• W4281996388 hasAuthorship W4281996388A5002676459 @default.
• W4281996388 hasAuthorship W4281996388A5003000553 @default.
• W4281996388 hasAuthorship W4281996388A5004020500 @default.
• W4281996388 hasAuthorship W4281996388A5013368889 @default.
• W4281996388 hasAuthorship W4281996388A5017416578 @default.
• W4281996388 hasAuthorship W4281996388A5019496707 @default.
• W4281996388 hasAuthorship W4281996388A5019911093 @default.
• W4281996388 hasAuthorship W4281996388A5021921614 @default.
• W4281996388 hasAuthorship W4281996388A5031520036 @default.
• W4281996388 hasAuthorship W4281996388A5032226480 @default.
• W4281996388 hasAuthorship W4281996388A5037244584 @default.
• W4281996388 hasAuthorship W4281996388A5041096535 @default.
• W4281996388 hasAuthorship W4281996388A5046393641 @default.
• W4281996388 hasAuthorship W4281996388A5051018235 @default.
• W4281996388 hasAuthorship W4281996388A5054614170 @default.
• W4281996388 hasAuthorship W4281996388A5057303452 @default.
• W4281996388 hasAuthorship W4281996388A5064456190 @default.
• W4281996388 hasAuthorship W4281996388A5069043826 @default.
• W4281996388 hasAuthorship W4281996388A5076344546 @default.
• W4281996388 hasAuthorship W4281996388A5081253005 @default.
• W4281996388 hasAuthorship W4281996388A5087140172 @default.
• W4281996388 hasAuthorship W4281996388A5088160001 @default.
• W4281996388 hasAuthorship W4281996388A5090138684 @default.
• W4281996388 hasBestOaLocation W42819963881 @default.
• W4281996388 hasConcept C150903083 @default.
• W4281996388 hasConcept C184235292 @default.
• W4281996388 hasConcept C207001950 @default.
• W4281996388 hasConcept C2777658100 @default.
• W4281996388 hasConcept C2778472372 @default.
• W4281996388 hasConcept C2781249067 @default.
• W4281996388 hasConcept C502942594 @default.
• W4281996388 hasConcept C57074206 @default.
• W4281996388 hasConcept C86803240 @default.
• W4281996388 hasConcept C95444343 @default.
• W4281996388 hasConcept C98274493 @default.
• W4281996388 hasConceptScore W4281996388C150903083 @default.
• W4281996388 hasConceptScore W4281996388C184235292 @default.
• W4281996388 hasConceptScore W4281996388C207001950 @default.
• W4281996388 hasConceptScore W4281996388C2777658100 @default.
• W4281996388 hasConceptScore W4281996388C2778472372 @default.
• W4281996388 hasConceptScore W4281996388C2781249067 @default.
• W4281996388 hasConceptScore W4281996388C502942594 @default.
• W4281996388 hasConceptScore W4281996388C57074206 @default.
• W4281996388 hasConceptScore W4281996388C86803240 @default.
• W4281996388 hasConceptScore W4281996388C95444343 @default.
• W4281996388 hasConceptScore W4281996388C98274493 @default.
• W4281996388 hasIssue "Supplement_1" @default.
• W4281996388 hasLocation W42819963881 @default.
• W4281996388 hasLocation W42819963882 @default.
• W4281996388 hasOpenAccess W4281996388 @default.
• W4281996388 hasPrimaryLocation W42819963881 @default.
• W4281996388 hasRelatedWork W2142019721 @default.
• W4281996388 hasRelatedWork W2162044478 @default.
• W4281996388 hasRelatedWork W2164992866 @default.
• W4281996388 hasRelatedWork W2165046781 @default.
• W4281996388 hasRelatedWork W2328771497 @default.
• W4281996388 hasRelatedWork W2594657632 @default.
• W4281996388 hasRelatedWork W2885961494 @default.
• W4281996388 hasRelatedWork W2940291671 @default.
• W4281996388 hasRelatedWork W4361946546 @default.
• W4281996388 hasRelatedWork W4361953392 @default.

• next